GDC-0032
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for GDC-0032, covering 2016-11-02 to 2024-07-31. Get the full timeline:
Most recent: Clinical Trial Update: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer [Phase 1]